JP2012176953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012176953A5 JP2012176953A5 JP2012087648A JP2012087648A JP2012176953A5 JP 2012176953 A5 JP2012176953 A5 JP 2012176953A5 JP 2012087648 A JP2012087648 A JP 2012087648A JP 2012087648 A JP2012087648 A JP 2012087648A JP 2012176953 A5 JP2012176953 A5 JP 2012176953A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- human
- fragment
- kir2dl1
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (20)
- ヒトＫＩＲ２ＤＬ１およびヒトＫＩＲ２ＤＬ２／３と交叉反応する、抗ＫＩＲ抗体またはその抗体断片であって、
（ａ）ＫＩＲ２ＤＳ４と結合しないか；
（ｂ）アミノ酸残基１０５，１０６，１０７，１０８，１０９，１１０，１１１，１２７，１２９，１３０，１３１，１３２，１３３，１３４，１３５，１５２，１５３，１５４，１５５，１５６，１５７，１５８，１５９，１６０，１６１，１６２，１６３，１８１および１９２によって規定されるエピトープ領域内において、ヒトＫＩＲ２ＤＬ１と結合するか；
（ｃ）Ｒ１３１がＡｌａによって置換されているヒトＫＩＲ２ＤＬ１の変異体と結合しないか；
（ｄ）Ｒ１５７がＡｌａによって置換されているヒトＫＩＲ２ＤＬ１の変異体と結合しないか；
（ｅ）Ｒ１５８がＡｌａによって置換されているヒトＫＩＲ２ＤＬ１の変異体と結合しないか；
（ｆ）ヒトＫＩＲ２ＤＬ１残基１３１、１５７および１５８に結合するか；または
（ｇ）Ｒ１３１がＴｒｐによって置換されているヒトＫＩＲ２ＤＳ３の変異体と結合するものの、野生型ＫＩＲ２ＤＳ３と結合せず、
ここにおいて、前記抗体またはその断片は、ヒトＫＩＲ２ＤＬ１および／またはヒトＫＩＲ２ＤＬ２／３によって媒介されるＮＫ細胞の細胞毒性の阻害を減少させ、中和しおよび／または逆転させ；および
ここにおいて、前記抗体断片は、Ｆａｂ断片、Ｆ（ａｂ’）２断片、Ｆｖ断片、Ｆ（ａｂ’）断片、二重特異性抗体および一本鎖抗体（ＳｃＦｖ）から選択される
抗ＫＩＲ抗体またはその抗体断片。 - ＫＩＲ２ＤＬ１および／またはＫＩＲ２ＤＬ２／３ヒト受容体への結合に関して、ＤＦ２００、１−７Ｆ９またはＮＫＶＳＦ１抗体と競合する請求項１に記載の抗体または抗体断片。
- ＫＩＲ２ＤＬ１ヒト受容体への結合に関して、ＥＢ６抗体と競合する請求項１に記載の抗体または抗体断片。
- ＫＩＲ２ＤＬ２／３ヒト受容体への結合に関して、ＧＬ１８３抗体と競合する請求項１に記載の抗体または抗体断片。
- 配列番号１または配列番号２に示されるアミノ酸配列を有する軽鎖可変領域を含む請求項１に記載の抗体または抗体断片。
- 配列番号３、配列番号４、配列番号５、配列番号６、配列番号７または配列番号８に示されるアミノ酸配列を有する１以上の軽鎖ＣＤＲを含む請求項１に記載の抗体または抗体断片。
- 配列番号９に示されるアミノ酸配列を有する重鎖可変領域を含む請求項１に記載の抗体または抗体断片。
- 配列番号１０、配列番号１１または配列番号１２に記載のアミノ酸配列を有する１以上の重鎖ＣＤＲを含む請求項１に記載の抗体または抗体断片。
- キメラ抗体、ヒト抗体またはヒト化抗体である請求項１から８の何れか１項に記載の抗体または抗体断片。
- トキシン、検出可能な部分、放射性同位体、造影剤または固相支持体に抱合されているか、または共有結合されている請求項１から８の何れか１項に記載の抗体または抗体断片を含む誘導体。
- ヒトＫＩＲ２ＤＬ１およびヒトＫＩＲ２ＤＬ２／３と交叉反応し、そのようなＫＩＲの阻害活性を中和する抗ＫＩＲ抗体または抗体断片であって、前記抗体は、ＫＩＲ２ＤＬ１および／またはＫＩＲ２ＤＬ２／３ヒト受容体への結合に関してＤＦ−２００抗体（寄託番号ＣＮＣＭ Ｉ−３２２４）と競合する抗体または抗体断片。
- 図１２に示される配列を有するＰａｎ２Ｄの軽鎖可変領域を含む請求項１１に記載の抗体または抗体断片。
- 図１２に示される配列を有するＰａｎ２Ｄの１以上の軽鎖可変領域ＣＤＲを含む請求項１１に記載の抗体または抗体断片。
- 図１２に示される配列を有するＰａｎ２Ｄの全ての軽鎖可変領域ＣＤＲを含む請求項１１に記載の抗体または抗体断片。
- 前記抗体はＰａｎ２Ｄである請求項１１に記載の抗体または抗体断片。
- （ａ）ＫＩＲ２ＤＳ４に結合せず、
（ｂ）アミノ酸残基１０５，１０６，１０７，１０８，１０９，１１０，１１１，１２７，１２９，１３０，１３１，１３２，１３３，１３４，１３５，１５２，１５３，１５４，１５５，１５６，１５７，１５８，１５９，１６０，１６１，１６２，１６３，１８１および１９２によって規定されるエピトープ領域内でヒトＫＩＲ２ＤＬ１に結合し、
（ｃ）Ｒ１３１がＡｌａで置換されているヒトＫＩＲ２ＤＬ１の変異体に結合せず、
（ｄ）Ｒ１５７がＡｌａで置換されているヒトＫＩＲ２ＤＬ１の変異体に結合せず、
（ｅ）Ｒ１５８がＡｌａで置換されているヒトＫＩＲ２ＤＬ１の変異体に結合せず、
（ｆ）ヒトＫＩＲ２ＤＬ１残基１３１，１５７および１５８に結合し、または
（ｇ）Ｒ１３１がＴｒｐで置換されているヒトＫＩＲ２ＤＳ３の変異体に結合するが、野生型ＫＩＲ２ＤＳ３に結合しない
請求項１１に記載の抗体または抗体断片。 - ＫＩＲ２ＤＬ１ヒト受容体への結合についてＥＢ６抗体と競合する請求項１１から１６の何れか１項に記載の抗体または抗体断片。
- ＫＩＲ２ＤＬ２／３ヒト受容体への結合についてＧＬ１８３抗体と競合する請求項１１から１７の何れか１項に記載の抗体または抗体断片。
- キメラ抗体、ヒト抗体またはヒト化抗体である請求項１１から１８の何れか１項に記載の抗体または抗体断片。
- 前記抗体断片は、Ｆａｂ断片、Ｆ（ａｂ’）２断片、Ｆｖ断片、Ｆ（ａｂ’）断片、二重特異性抗体、一本鎖抗体（ＳｃＦｖ）から成る群から選択される１つである請求項１１から１９の何れか１項に記載の抗体または抗体断片。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48389403P | 2003-07-02 | 2003-07-02 | |
| US60/483,894 | 2003-07-02 | ||
| US54547104P | 2004-02-19 | 2004-02-19 | |
| US60/545,471 | 2004-02-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515738A Division JP5015592B2 (ja) | 2003-07-02 | 2004-07-01 | Ｎｋ細胞活性を制御するための組成物及び方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015042824A Division JP6556465B2 (ja) | 2003-07-02 | 2015-03-04 | Ｎｋ細胞活性を制御するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012176953A JP2012176953A (ja) | 2012-09-13 |
| JP2012176953A5 true JP2012176953A5 (ja) | 2013-04-18 |
| JP5826697B2 JP5826697B2 (ja) | 2015-12-02 |
Family
ID=33567703
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006516606A Expired - Lifetime JP4871125B2 (ja) | 2003-07-02 | 2004-07-01 | Ｎｋ細胞活性を調節するための組成物および方法 |
| JP2006515738A Expired - Lifetime JP5015592B2 (ja) | 2003-07-02 | 2004-07-01 | Ｎｋ細胞活性を制御するための組成物及び方法 |
| JP2012087648A Expired - Lifetime JP5826697B2 (ja) | 2003-07-02 | 2012-04-06 | Ｎｋ細胞活性を制御するための組成物及び方法 |
| JP2015042824A Expired - Lifetime JP6556465B2 (ja) | 2003-07-02 | 2015-03-04 | Ｎｋ細胞活性を制御するための組成物及び方法 |
| JP2018078329A Pending JP2018153185A (ja) | 2003-07-02 | 2018-04-16 | Ｎｋ細胞活性を制御するための組成物及び方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006516606A Expired - Lifetime JP4871125B2 (ja) | 2003-07-02 | 2004-07-01 | Ｎｋ細胞活性を調節するための組成物および方法 |
| JP2006515738A Expired - Lifetime JP5015592B2 (ja) | 2003-07-02 | 2004-07-01 | Ｎｋ細胞活性を制御するための組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015042824A Expired - Lifetime JP6556465B2 (ja) | 2003-07-02 | 2015-03-04 | Ｎｋ細胞活性を制御するための組成物及び方法 |
| JP2018078329A Pending JP2018153185A (ja) | 2003-07-02 | 2018-04-16 | Ｎｋ細胞活性を制御するための組成物及び方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9902936B2 (ja) |
| EP (3) | EP2289939B1 (ja) |
| JP (5) | JP4871125B2 (ja) |
| KR (5) | KR20060079180A (ja) |
| CN (2) | CN103467602B (ja) |
| AT (1) | ATE490984T1 (ja) |
| AU (2) | AU2004253770C1 (ja) |
| BR (2) | BRPI0412138B8 (ja) |
| CA (2) | CA2530591A1 (ja) |
| CY (1) | CY1113394T1 (ja) |
| DE (1) | DE602004030464D1 (ja) |
| DK (2) | DK1639013T3 (ja) |
| ES (2) | ES2725526T3 (ja) |
| HK (1) | HK1091662A1 (ja) |
| HR (1) | HRP20120845T1 (ja) |
| IL (3) | IL172613A (ja) |
| MX (1) | MXPA05013923A (ja) |
| NO (4) | NO338818B1 (ja) |
| PL (1) | PL1639013T3 (ja) |
| PT (1) | PT1639013E (ja) |
| RU (2) | RU2404993C2 (ja) |
| WO (2) | WO2005003168A2 (ja) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090191213A9 (en) * | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
| PT1648507T (pt) | 2003-07-24 | 2017-03-20 | Innate Pharma Sa | Métodos e composições para aumentar a eficácia de anticorpos terapêuticos utilizando compostos potenciadores de células nk |
| AU2005238300A1 (en) * | 2004-04-30 | 2005-11-10 | Innate Pharma | Compositions and methods for treating proliferative disorders such as NK-type LDGL |
| ES2738578T3 (es) * | 2004-07-01 | 2020-01-23 | Novo Nordisk As | Anticuerpos contra el receptor NK PAN-KIR2DL y su uso en el diagnóstico y la terapia |
| AU2005259221B2 (en) * | 2004-07-01 | 2011-02-10 | Innate Pharma | Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use |
| CA3052445C (en) | 2004-07-10 | 2023-08-22 | Kerry S. Campbell | Genetically modified human natural killer cell lines |
| WO2006050270A2 (en) * | 2004-11-02 | 2006-05-11 | The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services | Compositions and methods for treating hyperproliferative disorders |
| ATE531733T1 (de) | 2005-01-06 | 2011-11-15 | Novo Nordisk As | Kir-bindende wirkstoffe und verfahren zu ihrer verwendung |
| PT1835937E (pt) | 2005-01-06 | 2012-06-25 | Novo Nordisk As | Composições e métodos para tratar infeção viral |
| US20090196850A1 (en) * | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
| EP2322557B1 (en) | 2005-10-14 | 2017-08-30 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| JP5478261B2 (ja) * | 2007-01-11 | 2014-04-23 | ノヴォ ノルディスク アクティーゼルスカブ | 抗ｋｉｒ抗体、製剤、およびその使用 |
| WO2010065939A1 (en) | 2008-12-05 | 2010-06-10 | Indiana University Research & Technology Corporation | Combination therapy to enhace nk cell mediated cytotoxicty |
| EP2808402A3 (en) * | 2008-12-29 | 2015-03-25 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Methods of predicting responsiveness to interferon treatment |
| WO2011096504A1 (ja) * | 2010-02-08 | 2011-08-11 | 株式会社日本バイオセラピー研究所 | Nk細胞強化型血液製剤の製造方法 |
| TWI664191B (zh) | 2010-11-22 | 2019-07-01 | 天賜製藥公司 | Ｎｋ細胞調節治療及治療血液惡性疾病之方法 |
| CN103717619B (zh) | 2011-05-25 | 2018-11-13 | 因内特制药股份有限公司 | 治疗发炎及自体免疫疾病之抗-kir抗体 |
| US20140234342A1 (en) | 2011-06-21 | 2014-08-21 | Innate Pharma | Nkp46-mediated nk cell tuning |
| JO3370B1 (ar) * | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
| EP3176178B1 (en) * | 2011-11-23 | 2019-01-30 | F. Hoffmann-La Roche AG | Cd40l expressing mammalian cells and their use |
| MX369148B (es) * | 2012-09-19 | 2019-10-30 | Innate Pharma | Agentes de unión kir3dl2. |
| NZ631405A (en) | 2012-10-02 | 2017-01-27 | Bristol Myers Squibb Co | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
| WO2015069785A1 (en) | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
| EP3187583B1 (en) * | 2014-08-29 | 2023-04-26 | National University Corporation Hokkaido University | Monoclonal antibody against kir2ds1 |
| EP3212227B1 (en) | 2014-10-28 | 2020-01-15 | Children's University Hospital Tübingen | Treatment of pediatric bcp-all patients with an anti-kir antibody |
| US10765699B2 (en) | 2015-02-06 | 2020-09-08 | National University Of Singapore | Methods for enhancing efficacy of therapeutic immune cells |
| US20160304607A1 (en) | 2015-04-17 | 2016-10-20 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| PL3291679T3 (pl) | 2015-05-06 | 2022-04-25 | Snipr Technologies Limited | Zmiana populacji drobnoustrojowych i modyfikowanie mikrobioty |
| MX2017016844A (es) | 2015-07-16 | 2018-08-15 | Biokine Therapeutics Ltd | Composiciones y procedimientos para tratar cancer. |
| EP3370768B9 (en) | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| US20190038713A1 (en) | 2015-11-07 | 2019-02-07 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| IL292302B2 (en) | 2016-05-20 | 2023-10-01 | Biohaven Pharm Holding Co Ltd | Use of glutamate modulating factors in cancer immunotherapy |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| EP3484516A4 (en) | 2016-07-14 | 2020-03-18 | Fred Hutchinson Cancer Research Center | MULTIPLE CONSTRUCTIONS OF BI-SPECIFIC LINK AREAS HAVING A DIFFERENT EPITOPE LINK TO TREAT CANCER |
| GB201616365D0 (en) * | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
| EP3518946A4 (en) | 2016-09-27 | 2020-09-09 | Board of Regents, The University of Texas System | METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME |
| US11278592B2 (en) | 2016-10-12 | 2022-03-22 | Board Of Regents, The University Of Texas System | Methods and compositions for TUSC2 immunotherapy |
| EP3529277A1 (en) | 2016-10-21 | 2019-08-28 | Innate Pharma | Treatment with anti-kir3dl2 agents |
| CN110381997A (zh) | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
| US20210101980A1 (en) | 2017-03-31 | 2021-04-08 | Bristol-Myers Squibb Company | Methods of treating tumor |
| US11655306B2 (en) | 2017-04-05 | 2023-05-23 | Korea Research Institute Of Bioscience And Biotechnology | NK cell-activating fusion protein, NK cell, and pharmaceutical composition including same |
| KR102376863B1 (ko) | 2017-05-12 | 2022-03-21 | 하푼 테라퓨틱스, 인크. | 메소텔린 결합 단백질 |
| CN107261304A (zh) * | 2017-06-05 | 2017-10-20 | 中国兽医药品监察所 | 一种奶牛的布鲁氏菌病免疫试剂盒及其应用 |
| CA3071282A1 (en) | 2017-08-10 | 2019-02-14 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| CN111465612A (zh) | 2017-10-13 | 2020-07-28 | 哈普恩治疗公司 | B细胞成熟抗原结合蛋白 |
| WO2019075468A1 (en) | 2017-10-15 | 2019-04-18 | Bristol-Myers Squibb Company | TUMOR TREATMENT METHODS |
| CN108060137B (zh) * | 2017-12-26 | 2021-07-02 | 博生吉医药科技(苏州)有限公司 | Il7和il21修饰的nk92细胞、制备方法及其应用 |
| CA3094329A1 (en) | 2018-03-19 | 2020-02-20 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
| JP7351845B2 (ja) | 2018-03-23 | 2023-09-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用 |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| EP3773685A1 (en) | 2018-03-25 | 2021-02-17 | SNIPR Biome ApS. | Treating & preventing microbial infections |
| KR20200139724A (ko) | 2018-03-30 | 2020-12-14 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| WO2020056170A1 (en) | 2018-09-12 | 2020-03-19 | Fred Hutchinson Cancer Research Center | Reducing cd33 expression to selectively protect therapeutic cells |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| MX2021007271A (es) | 2018-12-21 | 2021-07-15 | Onxeo | Nuevas moleculas de acido nucleico conjugado y sus usos. |
| KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
| KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
| JP2022534967A (ja) | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 多腫瘍遺伝子シグネチャーおよびその使用 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| CN111424012A (zh) * | 2020-03-30 | 2020-07-17 | 威海市中心医院 | 一种nk细胞培养用的饲养细胞去增殖能力的处理方法 |
| AR122644A1 (es) | 2020-06-19 | 2022-09-28 | Onxeo | Nuevas moléculas de ácido nucleico conjugado y sus usos |
| MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
| AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| US20240000837A1 (en) * | 2020-12-23 | 2024-01-04 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Inhibition of kir2dl2 for the enhancement of adoptive immunotherapies |
| US20220233693A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Antibody Compositions and Methods of Use Thereof |
| CA3196999A1 (en) | 2020-12-28 | 2022-07-07 | Masano HUANG | Methods of treating tumors |
| WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| EP4370552A1 (en) | 2021-07-13 | 2024-05-22 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| WO2023059333A1 (en) | 2021-10-08 | 2023-04-13 | 3M Innovative Properties Company | Slot die assembly with tuned stiffness, reduced draw zone, and force budget |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023110937A1 (en) | 2021-12-14 | 2023-06-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling |
| AU2022409713A1 (en) | 2021-12-16 | 2024-06-20 | Valerio Therapeutics | New conjugated nucleic acid molecules and their uses |
| WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| WO2024026385A1 (en) * | 2022-07-28 | 2024-02-01 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Inhibition of kir2dl2 and/or kir2dl3 for the enhancement of adoptive immunotherapies |
| WO2024090458A1 (ja) * | 2022-10-25 | 2024-05-02 | 第一三共株式会社 | 抑制型ｋｉｒに対するアゴニストを用いた免疫拒絶の回避方法 |
| WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| CN117883553A (zh) * | 2024-01-12 | 2024-04-16 | 成都医学院 | Pml-1蛋白在制备抑制细胞因子风暴的药物中的应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5776427A (en) * | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US5539094A (en) | 1993-11-12 | 1996-07-23 | La Jolla Cancer Research Foundation | DNA encoding Bcl-2-associated proteins |
| US5583034A (en) * | 1994-02-22 | 1996-12-10 | La Jolla Institute For Allergy And Immunology | Enhancement of adoptosis using antisense oligonucleotides |
| US5808028A (en) * | 1994-05-24 | 1998-09-15 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clone of a P58 receptor protein and uses thereof |
| NZ298145A (en) | 1994-12-29 | 1998-08-26 | Yamanouchi Pharma Co Ltd | Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament |
| US6750044B1 (en) | 1996-10-17 | 2004-06-15 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids |
| ATE334395T1 (de) * | 1998-10-29 | 2006-08-15 | Dakocytomation Denmark As | Nachweis von säure-resistenten mikroorganismen im stuhl |
| EP1179541B1 (en) * | 1999-04-28 | 2004-06-16 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| KR100419555B1 (ko) * | 2000-05-29 | 2004-02-19 | 주식회사유한양행 | 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자 |
| PT1648507T (pt) * | 2003-07-24 | 2017-03-20 | Innate Pharma Sa | Métodos e composições para aumentar a eficácia de anticorpos terapêuticos utilizando compostos potenciadores de células nk |
| AU2005259221B2 (en) | 2004-07-01 | 2011-02-10 | Innate Pharma | Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use |
| HUE026107T2 (en) * | 2004-12-28 | 2016-05-30 | Innate Pharma | Monoclonal antibody to NKG2A |
| ATE531733T1 (de) * | 2005-01-06 | 2011-11-15 | Novo Nordisk As | Kir-bindende wirkstoffe und verfahren zu ihrer verwendung |
| US20090196850A1 (en) * | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
| PT1835937E (pt) * | 2005-01-06 | 2012-06-25 | Novo Nordisk As | Composições e métodos para tratar infeção viral |
| EP2322557B1 (en) * | 2005-10-14 | 2017-08-30 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| JP5478261B2 (ja) | 2007-01-11 | 2014-04-23 | ノヴォ ノルディスク アクティーゼルスカブ | 抗ｋｉｒ抗体、製剤、およびその使用 |
| CN103717619B (zh) * | 2011-05-25 | 2018-11-13 | 因内特制药股份有限公司 | 治疗发炎及自体免疫疾病之抗-kir抗体 |
| EP2912063A1 (en) * | 2012-10-23 | 2015-09-02 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer |
| WO2015069785A1 (en) * | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
| US9884593B2 (en) * | 2015-02-12 | 2018-02-06 | Pro-Gard Products, Llc | Weapon mounting system |
-
2004
- 2004-07-01 MX MXPA05013923A patent/MXPA05013923A/es active IP Right Grant
- 2004-07-01 BR BRPI0412138A patent/BRPI0412138B8/pt active IP Right Grant
- 2004-07-01 KR KR1020067000025A patent/KR20060079180A/ko active Search and Examination
- 2004-07-01 PT PT47441159T patent/PT1639013E/pt unknown
- 2004-07-01 AU AU2004253770A patent/AU2004253770C1/en not_active Expired
- 2004-07-01 BR BRPI0412153A patent/BRPI0412153B8/pt active IP Right Grant
- 2004-07-01 ES ES10178580T patent/ES2725526T3/es not_active Expired - Lifetime
- 2004-07-01 WO PCT/DK2004/000470 patent/WO2005003168A2/en active Application Filing
- 2004-07-01 EP EP10178580.6A patent/EP2289939B1/en not_active Expired - Lifetime
- 2004-07-01 JP JP2006516606A patent/JP4871125B2/ja not_active Expired - Lifetime
- 2004-07-01 KR KR1020127013323A patent/KR101420344B1/ko active IP Right Grant
- 2004-07-01 RU RU2006102960/10A patent/RU2404993C2/ru active
- 2004-07-01 CA CA002530591A patent/CA2530591A1/en not_active Abandoned
- 2004-07-01 PL PL04744115T patent/PL1639013T3/pl unknown
- 2004-07-01 CA CA2530272A patent/CA2530272C/en not_active Expired - Lifetime
- 2004-07-01 ES ES04744115T patent/ES2393485T3/es not_active Expired - Lifetime
- 2004-07-01 CN CN201310392765.XA patent/CN103467602B/zh not_active Expired - Lifetime
- 2004-07-01 EP EP04738967A patent/EP1673397B1/en not_active Expired - Lifetime
- 2004-07-01 AU AU2004253630A patent/AU2004253630B2/en not_active Expired
- 2004-07-01 CN CN201310057089.0A patent/CN103588880B/zh not_active Expired - Lifetime
- 2004-07-01 KR KR1020127002275A patent/KR101325023B1/ko active IP Right Grant
- 2004-07-01 US US10/563,045 patent/US9902936B2/en active Active
- 2004-07-01 DK DK04744115.9T patent/DK1639013T3/da active
- 2004-07-01 WO PCT/IB2004/002464 patent/WO2005003172A2/en active Application Filing
- 2004-07-01 AT AT04738967T patent/ATE490984T1/de not_active IP Right Cessation
- 2004-07-01 RU RU2005140152/13A patent/RU2376315C2/ru active
- 2004-07-01 JP JP2006515738A patent/JP5015592B2/ja not_active Expired - Lifetime
- 2004-07-01 KR KR1020137013482A patent/KR101444717B1/ko active IP Right Grant
- 2004-07-01 DK DK04738967.1T patent/DK1673397T3/da active
- 2004-07-01 EP EP04744115A patent/EP1639013B1/en not_active Expired - Lifetime
- 2004-07-01 DE DE602004030464T patent/DE602004030464D1/de not_active Expired - Lifetime
- 2004-07-01 KR KR1020067000109A patent/KR101375153B1/ko active IP Right Grant
-
2005
- 2005-12-15 IL IL172613A patent/IL172613A/en active IP Right Grant
- 2005-12-19 NO NO20056048A patent/NO338818B1/no unknown
- 2005-12-20 IL IL172700A patent/IL172700A/en active IP Right Grant
-
2006
- 2006-02-01 NO NO20060528A patent/NO338255B1/no unknown
- 2006-07-18 HK HK06108029.2A patent/HK1091662A1/xx unknown
-
2012
- 2012-04-06 JP JP2012087648A patent/JP5826697B2/ja not_active Expired - Lifetime
- 2012-10-22 HR HRP20120845TT patent/HRP20120845T1/hr unknown
- 2012-11-28 CY CY20121101151T patent/CY1113394T1/el unknown
-
2015
- 2015-03-04 JP JP2015042824A patent/JP6556465B2/ja not_active Expired - Lifetime
- 2015-04-28 IL IL238490A patent/IL238490A0/en unknown
-
2016
- 2016-02-16 NO NO20160264A patent/NO342318B1/no unknown
- 2016-03-10 NO NO20160411A patent/NO343342B1/no unknown
-
2018
- 2018-01-22 US US15/876,839 patent/US11365393B2/en active Active
- 2018-04-16 JP JP2018078329A patent/JP2018153185A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012176953A5 (ja) | ||
| JP2015163068A5 (ja) | ||
| EP4286415A3 (en) | Humanized antigen-binding domains against cd19 and methods of use | |
| JP2013198490A5 (ja) | ||
| JP2017048240A5 (ja) | ||
| JP2017052784A5 (ja) | ||
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| JP2018516853A5 (ja) | ||
| JP2017114866A5 (ja) | ||
| JP2018510636A5 (ja) | ||
| WO2016207304A8 (en) | Monoclonal anti-il-1racp antibodies | |
| JP2019535670A5 (ja) | ||
| JP2017149720A5 (ja) | ||
| JP2009225799A5 (ja) | ||
| HRP20230411T1 (hr) | Dvostruko ciljanje | |
| JP2014205674A5 (ja) | ||
| JP2012502649A5 (ja) | ||
| JP2012116856A5 (ja) | ||
| JP2017504578A5 (ja) | ||
| JP2018520667A5 (ja) | ||
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| JP2013506428A5 (ja) | ||
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| NZ623706A (en) | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |